16:03 , Jan 15, 2018 |  BC Extra  |  Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine, Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors. Melanoma tumors with BRAF mutations that are -- or...